J. Pers. Med. 2013, 3(1), 40-69; doi:10.3390/jpm3010040
Review

Personalized Medicine in Ophthalmology: From Pharmacogenetic Biomarkers to Therapeutic and Dosage Optimization

1 Illumina Inc., San Diego, CA 92122, USA 2 Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA 3 Department of Ophthalmology, Chang Gung Memorial Hospital and College of Medicine, Chang Gung University, Taoyuan 333, Taiwan 4 Singapore Eye Research Institute, Singapore National Eye Centre, 168751, Singapore 5 Department of Ophthalmology, Yong Loo Lin School of Medicine, National University of Singapore and National University Health System, 119074, Singapore 6 Departments of Pathology and Laboratory Medicine, Pediatrics and Human Genetics, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA 7 Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA 8 Department of Pediatrics and Human Genetics, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA These authors contributed equally to this work.
* Author to whom correspondence should be addressed.
Received: 15 January 2013; Accepted: 22 February 2013 / Published: 5 March 2013
(This article belongs to the Special Issue Dosage Personalization in Modern Medicine)
PDF Full-text Download PDF Full-Text [474 KB, Updated Version, uploaded 6 March 2013 15:34 CET]
The original version is still available [474 KB, uploaded 5 March 2013 12:01 CET]
Abstract: Rapid progress in genomics and nanotechnology continue to advance our approach to patient care, from diagnosis and prognosis, to targeting and personalization of therapeutics. However, the clinical application of molecular diagnostics in ophthalmology has been limited even though there have been demonstrations of disease risk and pharmacogenetic associations. There is a high clinical need for therapeutic personalization and dosage optimization in ophthalmology and may be the focus of individualized medicine in this specialty. In several retinal conditions, such as age-related macular degeneration, diabetic macular edema, retinal vein occlusion and pre-threshold retinopathy of prematurity, anti-vascular endothelial growth factor therapeutics have resulted in enhanced outcomes. In glaucoma, recent advances in cytoskeletal agents and prostaglandin molecules that affect outflow and remodel the trabecular meshwork have demonstrated improved intraocular pressure control. Application of recent developments in nanoemulsion and polymeric micelle for targeted delivery and drug release are models of dosage optimization, increasing efficacy and improving outcomes in these major eye diseases.
Keywords: personalized medicine; pharmacogenetics; clinical utility; ophthalmology; VEGF; age-related macular degeneration; glaucoma; retinopathy; drug delivery; nanotechnology

Article Statistics

Load and display the download statistics.

Citations to this Article

Cite This Article

MDPI and ACS Style

Ong, F.S.; Kuo, J.Z.; Wu, W.-C.; Cheng, C.-Y.; Blackwell, W.-L.B.; Taylor, B.L.; Grody, W.W.; Rotter, J.I.; Lai, C.-C.; Wong, T.Y. Personalized Medicine in Ophthalmology: From Pharmacogenetic Biomarkers to Therapeutic and Dosage Optimization. J. Pers. Med. 2013, 3, 40-69.

AMA Style

Ong FS, Kuo JZ, Wu W-C, Cheng C-Y, Blackwell W-LB, Taylor BL, Grody WW, Rotter JI, Lai C-C, Wong TY. Personalized Medicine in Ophthalmology: From Pharmacogenetic Biomarkers to Therapeutic and Dosage Optimization. Journal of Personalized Medicine. 2013; 3(1):40-69.

Chicago/Turabian Style

Ong, Frank S.; Kuo, Jane Z.; Wu, Wei-Chi; Cheng, Ching-Yu; Blackwell, Wendell-Lamar B.; Taylor, Brian L.; Grody, Wayne W.; Rotter, Jerome I.; Lai, Chi-Chun; Wong, Tien Y. 2013. "Personalized Medicine in Ophthalmology: From Pharmacogenetic Biomarkers to Therapeutic and Dosage Optimization." J. Pers. Med. 3, no. 1: 40-69.

J. Pers. Med. EISSN 2075-4426 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert